Drugs / SRP-3D (diethylamide)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05484414 | Jul → Dec 2025 overdue | — | South Rampart Pharma, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRP-3D (diethylamide) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05484414 ↗ |
| Route | Oral | “Oral Doses of SRP-3D (DA)” NCT05484414 ↗ |